{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T14:43:26Z","timestamp":1775486606203,"version":"3.50.1"},"reference-count":22,"publisher":"The Journal of Rheumatology","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"accepted":{"date-parts":[[2023,12,19]]},"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>Current recommendations for the management of patients with axial spondyloarthritis (axSpA) emphasize the need of an individualized strategy in therapeutic decision-making. The study objectives were to describe therapeutic strategies observed in axSpA, and to assess the factors associated with treatment intensification over time.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We included patients with axSpA from the French prospective cohort DESIR (<jats:italic>Devenir des Spondylarthropathies Indiff\u00e9renci\u00e9es R\u00e9centes<\/jats:italic>), with a scheduled 10-year follow-up. A multistate model with 4 ordered treatment states (no treatment, nonsteroidal antiinflammatory drugs [NSAIDs], conventional synthetic disease-modifying antirheumatic drugs [csDMARDs], and tumor necrosis factor inhibitors [TNFi]) was defined, with 6 possible transitions. Restricted mean sojourn times in each state were estimated. Then, predictors of those transitions were assessed by multivariable Cox models.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 686\/708 (96.9%) patients who had &gt; 1 visit were analyzed. At cohort entry, 199 (29%) were untreated, 427 (62.2%) were receiving NSAIDs, 60 (8.7%) csDMARDs, and none were receiving TNFi. Over the follow-up period, patients mostly (46.4% of the time) received NSAIDs, followed by TNFi (24.4% of the time). The presence of sacroiliitis on radiographs, inflammatory bowel disease, and articular index were jointly associated with the transition to NSAIDs. Longer duration in the previous state often decreased the hazard of the transition to csDMARDs or TNFi. Worse disease activity outcomes increased the hazard of most transitions.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>To our knowledge, this was the first study using a multistate model to easily represent different treatment states, detailing the transitions across them and their associated factors. Different time profiles for the management of patients with axSpA were identified, including in those abstaining from treatment up to a significant proportion of patients treated with csDMARDs.<\/jats:p><\/jats:sec>","DOI":"10.3899\/jrheum.2023-0933","type":"journal-article","created":{"date-parts":[[2024,2,15]],"date-time":"2024-02-15T13:25:50Z","timestamp":1708003550000},"page":"368-377","source":"Crossref","is-referenced-by-count":5,"title":["Factors Associated With Treatment Pathways in Early Axial Spondyloarthritis: A Multistate Analysis of the 10-Year Follow-Up of the DESIR Cohort"],"prefix":"10.3899","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4698-045X","authenticated-orcid":false,"given":"Elodie","family":"Portier","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6449-4730","authenticated-orcid":false,"given":"Sylvie","family":"Chevret","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2714-6600","authenticated-orcid":false,"given":"Anouk","family":"Walter-Petrich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9815-2138","authenticated-orcid":false,"given":"Adeline","family":"Ruyssen-Witrand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3009-6229","authenticated-orcid":false,"given":"Maxime","family":"Dougados","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2246-1986","authenticated-orcid":false,"given":"Anna","family":"Molt\u00f3","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2262","published-online":{"date-parts":[[2024,2,15]]},"reference":[{"key":"2024040105251571000_51.4.368.1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210770"},{"key":"2024040105251571000_51.4.368.2","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223296"},{"key":"2024040105251571000_51.4.368.3","doi-asserted-by":"crossref","first-page":"105344","DOI":"10.1016\/j.jbspin.2022.105344","article-title":"2022 French Society for Rheumatology (SFR) recommendations on the everyday management of patients with spondyloarthritis, including psoriatic arthritis","volume":"89","author":"Wendling","year":"2022","journal-title":"Joint Bone Spine"},{"key":"2024040105251571000_51.4.368.4","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211734"},{"key":"2024040105251571000_51.4.368.5","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-219585"},{"key":"2024040105251571000_51.4.368.6","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209785"},{"key":"2024040105251571000_51.4.368.7","unstructured":"Leslie B , Molto A , Gossec L , Matthieu R. Different disease activity trajectories in early axial spondyloarthritis lead to significantly different long-term outcomes: a cluster-based analysis of the DESIR cohort [abstract]. Arthritis Rheumatol 2020;72 Suppl 10."},{"key":"2024040105251571000_51.4.368.8","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/s13075-019-1927-6","article-title":"Evaluation of concomitant peripheral arthritis in patients with recent onset axial spondyloarthritis: 5-year results from the DESIR cohort","volume":"21","author":"L\u00f3pez-Medina","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"2024040105251571000_51.4.368.9","first-page":"561","article-title":"Clinical peripheral enthesitis in the DESIR prospective longitudinal axial spondyloarthritis cohort","volume":"37","author":"Nadon","year":"2019","journal-title":"Clin Exp Rheumatol"},{"key":"2024040105251571000_51.4.368.10","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.181331"},{"key":"2024040105251571000_51.4.368.11","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22001"},{"key":"2024040105251571000_51.4.368.12","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jbspin.2020.02.004","article-title":"Patients with axial spondyloarthritis report significant differences between men and women and high impact of the disease: large websurvey analysis","volume":"87","author":"Ib\u00e1\u00f1ez Vodnizza","year":"2020","journal-title":"Joint Bone Spine"},{"key":"2024040105251571000_51.4.368.13","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.semarthrit.2017.01.005","article-title":"Frequency of concomitant fibromyalgia in rheumatic diseases: monocentric study of 691 patients","volume":"47","author":"Fan","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"2024040105251571000_51.4.368.14","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780380104"},{"key":"2024040105251571000_51.4.368.15","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s13075-016-0943-z","article-title":"Evaluation of the impact of fibromyalgia in disease activity and treatment effect in spondyloarthritis","volume":"18","author":"Bello","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"2024040105251571000_51.4.368.16","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-212378"},{"key":"2024040105251571000_51.4.368.17","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-214259"},{"key":"2024040105251571000_51.4.368.18","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1093\/rheumatology\/keab638","article-title":"Individual-level and country-level socio-economic factors and health outcomes in spondyloarthritis: analysis of the ASAS-perSpA study","volume":"61","author":"Capelusnik","year":"2022","journal-title":"Rheumatology"},{"key":"2024040105251571000_51.4.368.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2015.02.006"},{"key":"2024040105251571000_51.4.368.20","first-page":"1043","article-title":"Evaluation of extreme patient-reported outcome in early spondyloarthritis and its impact on the effect of TNF-\u03b1 blockers treatment","volume":"36","author":"Meghnathi","year":"2018","journal-title":"Clin Exp Rheumatol"},{"key":"2024040105251571000_51.4.368.21","doi-asserted-by":"publisher","DOI":"10.1002\/sim.2712"},{"key":"2024040105251571000_51.4.368.22","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.4054\/DemRes.2014.30.62","article-title":"A note on computing average state occupation times","volume":"30","author":"Beyersmann","year":"2014","journal-title":"Demogr Res"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.2023-0933","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T12:27:47Z","timestamp":1711974467000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.2023-0933"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,15]]},"references-count":22,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,4,1]]},"published-print":{"date-parts":[[2024,4]]}},"alternative-id":["10.3899\/jrheum.2023-0933"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.2023-0933","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,15]]}}}